D
Donald E. Hricik
Researcher at Case Western Reserve University
Publications - 168
Citations - 8139
Donald E. Hricik is an academic researcher from Case Western Reserve University. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 50, co-authored 167 publications receiving 7737 citations. Previous affiliations of Donald E. Hricik include University Hospitals of Cleveland & University of Minnesota.
Papers
More filters
Journal Article
Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes.
Peter S. Heeger,Neil S. Greenspan,Shannon Kuhlenschmidt,Cora Dejelo,Donald E. Hricik,James A. Schulak,Magdalena Tary-Lehmann +6 more
TL;DR: Improved ability to define the strength of the allospecific immune response by enzyme-linked immunospot assay may allow improved pairing of recipients with donors and identification of kidney allograft donor-recipient pairs at high risk for acute rejection, thus permitting targeted interventions aimed at prolonging graft survival.
Journal ArticleDOI
Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy
Tomas Berl,Lawrence G. Hunsicker,Julia B. Lewis,Marc A. Pfeffer,Jerome G. Porush,Jean L. Rouleau,Paul L. Drury,Enric Esmatjes,Donald E. Hricik,Chirag R. Parikh,Itamar Raz,Philippe Vanhille,Thomas B. Wiegmann,Bernard M. Wolfe,Francesco Locatelli,Samuel Z. Goldhaber,Edmund J. Lewis +16 more
TL;DR: The analysis of the cardiovascular end points that were monitored as secondary end points in the Irbesartan Diabetic Nephropathy Trial (IDNT) was reported to assess whether an angiotensin II receptor blocker or a calcium-channel blocker alters the risk for cardiovascular events beyond those observed by blood pressure reduction alone without such agents.
Journal ArticleDOI
Impact of Achieved Blood Pressure on Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial
Tomas Berl,Lawrence G. Hunsicker,Julia B. Lewis,Marc A. Pfeffer,Jerome G. Porush,Jean-Lucien Rouleau,Paul L. Drury,Enric Esmatjes,Donald E. Hricik,Marc Pohl,Itamar Raz,Philippe Vanhille,Thomas B. Wiegmann,Bernard M. Wolfe,Francesco Locatelli,Samuel Z. Goldhaber,Edmund J. Lewis +16 more
TL;DR: It is concluded that achieved systolic BP approaching 120mmHg and diastolic BP of 85 mmHg are associated with the best protection against CV events in patients with diabetic nephropathy.
Journal ArticleDOI
Urinary-Cell mRNA Profile and Acute Cellular Rejection in Kidney Allografts
Manikkam Suthanthiran,Joseph E. Schwartz,Ruchuang Ding,Michael Abecassis,Darshana Dadhania,Benjamin Samstein,Stuart J. Knechtle,John J. Friedewald,Yolanda T. Becker,Vijay K. Sharma,N. Williams,C. Chang,Christine Hoang,Thangamani Muthukumar,Phyllis August,Karen Keslar,Robert L. Fairchild,Donald E. Hricik,Peter S. Heeger,Leiya Han,Jun Liu,Michael Riggs,David Ikle,Nancy D. Bridges,Abraham Shaked +24 more
TL;DR: A molecular signature of CD3ε mRNA, IP-10 mRNA, and 18S rRNA levels in urinary cells appears to be diagnostic and prognostic of acute cellular rejection in kidney allografts.
Journal ArticleDOI
Prednisone withdrawal, in kidney transplant recipients on cyclosporine and mycophenolate mofetil - A prospective randomized study
Nasimul Ahsan,Donald E. Hricik,Arthur J. Matas,Stephen Rose,Stephen J. Tomlanovich,Alan H. Wilkinson,Marian Ewell,Matthew McIntosh,Donald Stablein,Ernest E. Hodge,Daniel H. Hayes,Paul F. Gores,David M. Cohen,Thomas A. Gonwa,Karl Brinler,Robert C. Harland,John F. Neylan,Mark D. Pescovitz,James J. Wynn,Harold C-Yang,William M. Bennett,John B. Copley,John Dunn,S. Tomlanovich,Lawrence Chan,J. Andrew Bertolatus,Mathew R. Weir,Robert Mendez,John D. Pirsch,J. Harold Helderman +29 more
TL;DR: For recipients on cyclosporine/mycophenolate mofetil/P with no AR at 90 days, the chance of developing subsequent AR is small; if P is tapered and withdrawn, the risk increases, but the majority remain free of acute and chronic rejection.